This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
January 30, 2025: “The U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.
Lupin has announced that the United States Food and Drug Administration (U.S. FDA) has completed a Pre-Approval Inspection (PAI) of Edaravone Oral Suspension, 105 mg/5 mL, at its manufacturing facility in Somerset, New Jersey. The inspection was conducted from January 28 to February 1, 2025, and concluded with zero 483 observations. Commenting on the development, Nilesh Gupta, Managing Director, Lupin, said, The successful outcome of the U.S.
By Sara M Keup In reviewing some new 2025 pharmacy rules/laws a couple interesting changes caught this bloggers attention: As of December 30, 2024, Missouri has rolled out new rules related to prescription drug delivery requirements. The rules were implemented to enhance patient safety protections via revised drug handling, packaging, and delivery requirements.
In this episode, I’ll discuss the use of methylene blue for the treatment of refractory anaphylaxis without hypotension. Episode 997: The use of methylene blue for the treatment of refractory anaphylaxis without hypotension Subscribe on iTunes , Android , or Stitcher Methylene blue has some unique uses such as in the treatment of acquired methemoglobinemia and vasoplegia after cardiac surgery.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
Sanjaya Mariwala, President of the IMC Chamber of Commerce and Industry and Executive Chairman & Managing Director of OmniActive Health Technologies: “The Union Budget delivered today showcases a clear vision for Indias economic future. The reforms in income tax structure will put more money in the citizens pockets, creating a cycle of spending and growth.
On Saturday, President Trump ordered import taxes on goods from Canada, China, and Mexico, a move that could raise costs for consumers across the economy, including in health care. Tariffs of 25% on imports from Canada (except energy) and Mexico, and 10% on goods from China take effect on Tuesday. Trump said the tariffs will remain in place until those countries stop the flow of fentanyl and undocumented immigrants into the United States.
On Sunday, the National Science Foundation announced that its payment system was back online to comply with a judge’s order, five days after the agency froze funding to researchers. While post-doctoral fellows were relieved that they could now request the checks they rely on to pay for rent, food, and credit card bills, some remain concerned about what they see as contradictory messages that the funding agency has put out, and worry their grants and livelihoods may still be at risk.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content